Belpointe Asset Management LLC Has $194,000 Position in Sanofi (NASDAQ:SNY)

Belpointe Asset Management LLC reduced its stake in Sanofi (NASDAQ:SNY) by 5.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,023 shares of the company’s stock after selling 238 shares during the period. Belpointe Asset Management LLC’s holdings in Sanofi were worth $194,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Arkadios Wealth Advisors raised its holdings in Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after buying an additional 751 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after acquiring an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Kentucky Trust Co acquired a new position in Sanofi during the 4th quarter valued at about $436,000. Finally, World Investment Advisors LLC increased its holdings in Sanofi by 1,020.5% during the 3rd quarter. World Investment Advisors LLC now owns 48,430 shares of the company’s stock worth $2,791,000 after purchasing an additional 44,108 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Trading Up 0.7 %

NASDAQ SNY opened at $50.90 on Friday. The business’s fifty day moving average is $54.79 and its 200-day moving average is $52.24. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a market capitalization of $128.59 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a one year low of $45.22 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be issued a dividend of $2.0369 per share. This represents a yield of 3.1%. This is a positive change from Sanofi’s previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi’s dividend payout ratio is 59.04%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. The Goldman Sachs Group began coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price for the company. Finally, BNP Paribas began coverage on shares of Sanofi in a report on Tuesday. They set an “outperform” rating and a $65.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.